GENERIC NAME formulation (Brand name®▼) for some indication

# The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of GENERIC NAME formulation (Brand name®▼) for some indication.

## GREY

Do not repeat statement in box above. Only add a similar statement if extra information included as clarification. If it is a new drug, it may be useful to add some information about licensed use.

Add a statement as appropriate, e.g.

* This recommendation will be reviewed within 6 months of the product launch in the UK market, following a full assessment of the evidence by the New Medicines Sub Group.
* This recommendation will be reviewed within 6 months by the Formulary and Guidelines/New Medicines Subgroup.
* This recommendation will be reviewed when the NICE TA/CG is published. This is expected to be in xxxx.
* This recommendation will be reviewed when the relevant formulary chapter is reviewed or earlier if there is significant new evidence relating to this recommendation.
* This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

Outline current alternative treatments and reference any relevant national or local guidance also available on the same subject matter (hyperlink or ask for hyperlink to be inserted in final version). When quoting NICE guidance make reference to the TA/GC number and the date published.

### References

1. Reference 1 with hyperlink
2. Reference 2 with hyperlink